Biofrontera (BFRI) Set to Release Earnings on Wednesday

Biofrontera (NASDAQ:BFRI) is anticipated to issue its Q3 2026 results before the market opens on Wednesday, November 11th. Analysts expect the company to post earnings of ($0.22) per share and revenue of $8.25 million for the quarter. Interested persons may visit the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Thursday, November 12, 2026 at 10:00 AM ET.

Biofrontera (NASDAQ:BFRI) last released its quarterly earnings results on Thursday, August 13th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.05. Biofrontera had a negative return on equity of 145.81% and a negative net margin of 13.78%. The business had revenue of $12.00 million during the quarter, compared to the consensus estimate of $9.50 million. On average, analysts expect Biofrontera to post ($0.60) EPS for the current fiscal year and ($0.03) EPS for the next fiscal year.

Biofrontera Stock Up 2.3%

Shares of NASDAQ BFRI opened at $0.89 on Wednesday. The company has a quick ratio of 1.08, a current ratio of 1.18 and a debt-to-equity ratio of 0.78. The stock’s fifty day moving average price is $1.13 and its two-hundred day moving average price is $1.03. Biofrontera has a one year low of $0.55 and a one year high of $1.66.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Biofrontera in a report on Tuesday, October 13th. Zacks Research upgraded shares of Biofrontera from a “strong sell” rating to a “hold” rating in a research note on Monday, August 3rd. Finally, Wall Street Zen lowered shares of Biofrontera from a “buy” rating to a “hold” rating in a research report on Sunday, September 20th. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold”.

Biofrontera Company Profile

Biofrontera Inc (NASDAQ:BFRI) is a specialty pharmaceutical company focused on developing and commercializing prescription dermatology products, with an emphasis on treatments for precancerous and cancerous skin conditions. The company primarily serves the U.S. dermatology market through a commercial organization that supports physicians and other healthcare providers.

Biofrontera’s principal product is Ameluz (aminolevulinic acid hydrochloride) topical gel, a prescription medication used with photodynamic therapy to treat actinic keratoses.